Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia

This article was originally published in The Tan Sheet

Executive Summary

Rogaine third quarter U.S. sales reached $24 mil., a 25% decline, and $32 mil. worldwide, down 18% from the year-ago period, company reports Oct. 30. Pharmacia's marketing exclusivity for the hair regrowth formula expires Nov. 14; Perrigo recently postponed launch of its private label minoxidil 5% (1"The Tan Sheet" Oct. 30. p. 13). Revenue from U.S. sales of Nicorette reached $21 mil. in the quarter, up 5%, with flat worldwide sales of $50 mil. Pharmacia recently acquired the Nicotrol smoking cessation brand from McNeil (2"The Tan Sheet" Oct. 23, p. 6). Pharmacia net sales totaled $4.3 bil. in the quarter, up 15%, with net earnings up 61% to $427 mil

You may also be interested in...



Perrigo New Product Program, Quality Control Back On Track In FY 2002

Corrective actions taken in response to an unfavorable FDA inspection of Perrigo's Allegan, Mich. facility will preclude the planned November launch of minoxidil 5% and stall the company's pipeline, Perrigo told analysts in an Oct. 25 conference call.

J&J/Merck Pepcid Complete Combines H2 Antagonist/Antacid Ingredients

J&J/Merck's Pepcid Complete is the first OTC stomach remedy to combine a fast-acting antacid ingredient with a long-term acid control ingredient, according to the firm. FDA approved NDA 20-958 for Pepcid Complete Oct. 16.

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS091863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel